# Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®

> **NCT00542880** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 442 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
- **DRUG:** Seretide Diskus (salmeterol/fluticasone) 50/500 μg

## Key facts

- **NCT ID:** NCT00542880
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 442 (ACTUAL)
- **Last updated:** 2012-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542880, "Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00542880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*